Aspirin Effectiveness Testing Now Available Nationwide

Business Wire, August 27, 2007

Corgenix AspirinWorks([R]) Test Kit Offered Through LabCorp([R]) and Other Clinical Labs

DENVER -- Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, has announced that its recently FDA cleared AspirinWorks([R]) Test Kit is available to doctors nationwide.

"We are pleased that AspirinWorks testing is now offered nationally through the LabCorp network of laboratories, making the test available to virtually every physician in the U.S.," said Corgenix' Clinical Affairs Director Gordon Ens. "This is in addition to our growing list of other clinical laboratories offering the test, such as Emory University in Atlanta."

The new test, which was launched nationwide in June following FDA 510(k) clearance, measures aspirin effectiveness on platelets through direct measurement of thromboxane production (aspirin's target). The stickier the blood platelets, the less impact the aspirin is having. This crucial information allows physicians to individualize a patient's therapy.

Unlike other platelet tests, which require freshly drawn blood that must be evaluated within at least 4 hours, the AspirinWorks test only requires a urine sample that can be obtained in any doctor's office, making the test easy for both physician and patient.

"In the past few months, we have experienced a rapid increase in public interest for the AspirinWorks test," said Douglass Simpson, Corgenix' President and Chief Executive Officer. "There is growing acceptance among physicians to test for aspirin effectiveness, and we expect that by the end of 2007 a significant number of the most important clinical labs will be routinely running this test."

Simpson said that recently released supporting clinical data, coupled with several scientific articles scheduled for publication later in 2007 and 2008, will further enhance the science and clinical validation behind aspirin effectiveness testing.

Clinical data on AspirinWorks was released earlier in the summer at the Congress of the International Society on Thrombosis and Hemostasis (ISTH) meeting in Geneva, Switzerland. The studies focused on patients undergoing percutaneous coronary intervention (PTCA) and diabetics with coronary artery disease (CAD). The AspirinWorks product will also be featured at several upcoming scientific meetings, including the European Society of Cardiology in September, the American Academy of Family Practice in October and the American Heart Association in November.

In a recent BusinessWeek article, Dr. Alexander Duncan, Director of Special Hemostasis Labs at Atlanta's Emory University, said, "This is the first time there is a simple-to-use lab test to measure the efficacy of aspirin." Emory University's lab is one of the first in the U.S. to implement the test.

The AspirinWorks Test Kit is an enzyme-linked immunoassay (ELISA) to determine levels of 11-Dehydro Thromboxane B2 (11dhTxB2) in human urine, which aids in the qualitative detection of aspirin effect in apparently healthy individuals post ingestion. The test kit targets a potential U.S. market of over 60 million individuals currently taking aspirin, and a potential global market exceeding 200 million individuals.

Physicians and laboratories interested in ordering the test can call 1-800-729-5661 x180, or e-mail info@aspirinworks.com. More information is also available at www.aspirinworks.com.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network. More information is available at www.corgenix.com.

Statements in this press release that are not strictly historical facts are "forward looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.

LabCorp[R] is a registered trademark of Laboratory Corporation of America[R] Holdings.

Note to editors: the "2" in Thromboxane B2 and (11dhTxB2) should be subscript.